Patents Assigned to KADMON PHARMACEUTICALS LLC
  • Stable trientine formulations
    Patent number: 10874624
    Abstract: Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging. The sealed packaging provides a high barrier protection against air, moisture and light and prevents exposure of the drug to conditions that facilitate its decomposition. The pharmaceutical dosage forms are useful for treating diseases or conditions where excess copper is not removed from the body, e.g., Wilson's disease.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 29, 2020
    Assignee: KADMON PHARMACEUTICALS, LLC
    Inventor: Samuel D. Waksal
  • ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
    Publication number: 20140363396
    Abstract: Hepatitis C is treated by administering once daily ribavirin, taribavirin, other derivatives or pharmaceutically acceptable salts thereof. Hepatitis C may also be treated by administering any of the foregoing compounds once daily in combination with interferon and/or direct-acting antivirals. Once daily dosage forms administered for treating hepatitis C may comprise between 800 mg and 1400 of ribavirin. Once daily dosage forms administered for treating hepatitis C may also comprise between 800 mg and 4000 mg of taribavirin.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 11, 2014
    Applicant: KADMON PHARMACEUTICALS LLC
    Inventor: Samuel Waksal